Change in the hepatic profile of hepatitis C virus genotype 4–infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE‐II study

In AGATE‐II, treatment with ombitasvir coformulated with paritaprevir/ritonavir plus ribavirin (RBV) in Egyptians infected with hepatitis C virus genotype 4 resulted in high rates of sustained virologic response at post‐treatment week 12. This subanalysis examined the effects of treatment in AGATE‐I...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of medical virology 2018-11, Vol.90 (11), p.1739-1744
Hauptverfasser:	Waked, Imam, Esmat, Gamal, Fouad, Rabab, Allam, Naglaa, Hassany, Mohamed, Mohey, Mohammad, Shiha, Gamal, Soliman, Reham, Qaqish, Roula B., Hall, Coleen, Alami, Negar N., Kopecky‐Bromberg, Sarah, Mobashery, Niloufar
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Alanine Alanine transaminase Alanine Transaminase - blood Anilides - therapeutic use Antiretroviral drugs Antiviral Agents - therapeutic use Antiviral drugs Aspartate aminotransferase Aspartate Aminotransferases - blood Biomarkers Carbamates - therapeutic use chronic hepatitis C Cirrhosis compensated cirrhosis direct‐acting antivirals (DAAs) Drug Therapy, Combination - methods Female Fibrosis Genotype Genotype & phenotype genotype 4 Genotypes Hepacivirus - classification Hepacivirus - genetics Hepacivirus - isolation & purification Hepatitis Hepatitis C Hepatitis C, Chronic - complications Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - virology Humans Interferon Liver Liver - pathology liver biomarkers Liver cirrhosis Liver Cirrhosis - pathology Macrocyclic Compounds - therapeutic use Male Middle Aged Patients Ribavirin Ribavirin - therapeutic use Ritonavir Ritonavir - therapeutic use Sustained Virologic Response Treatment Outcome Virology Viruses Weight
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!